Baynes JW - Search Results

1

Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.

Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW. Degenhardt TP, et al. Among authors: baynes jw. Kidney Int. 2002 Mar;61(3):939-50. doi: 10.1046/j.1523-1755.2002.00207.x. Kidney Int. 2002. PMID: 11849448 Free article.

2

Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications.

Metz TO, Alderson NL, Chachich ME, Thorpe SR, Baynes JW. Metz TO, et al. Among authors: baynes jw. J Biol Chem. 2003 Oct 24;278(43):42012-9. doi: 10.1074/jbc.M304292200. Epub 2003 Aug 15. J Biol Chem. 2003. PMID: 12923193 Free article.

3

Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications.

Metz TO, Alderson NL, Thorpe SR, Baynes JW. Metz TO, et al. Among authors: baynes jw. Arch Biochem Biophys. 2003 Nov 1;419(1):41-9. doi: 10.1016/j.abb.2003.08.021. Arch Biochem Biophys. 2003. PMID: 14568007 Review.

4

Chemical modification of proteins during peroxidation of phospholipids.

Januszewski AS, Alderson NL, Jenkins AJ, Thorpe SR, Baynes JW. Januszewski AS, et al. Among authors: baynes jw. J Lipid Res. 2005 Jul;46(7):1440-9. doi: 10.1194/jlr.M400442-JLR200. Epub 2005 Apr 1. J Lipid Res. 2005. PMID: 15805546 Free article.

5

S-(2-Succinyl)cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate.

Alderson NL, Wang Y, Blatnik M, Frizzell N, Walla MD, Lyons TJ, Alt N, Carson JA, Nagai R, Thorpe SR, Baynes JW. Alderson NL, et al. Among authors: baynes jw. Arch Biochem Biophys. 2006 Jun 1;450(1):1-8. doi: 10.1016/j.abb.2006.03.005. Epub 2006 Mar 22. Arch Biochem Biophys. 2006. PMID: 16624247

6

The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats.

Alderson NL, Chachich ME, Youssef NN, Beattie RJ, Nachtigal M, Thorpe SR, Baynes JW. Alderson NL, et al. Among authors: baynes jw. Kidney Int. 2003 Jun;63(6):2123-33. doi: 10.1046/j.1523-1755.2003.00027.x. Kidney Int. 2003. PMID: 12753299 Free article.

7

Role of the Maillard reaction in diabetes mellitus and diseases of aging.

Thorpe SR, Baynes JW. Thorpe SR, et al. Among authors: baynes jw. Drugs Aging. 1996 Aug;9(2):69-77. doi: 10.2165/00002512-199609020-00001. Drugs Aging. 1996. PMID: 8820792 Review.

8

Technical note. The serum concentration of the advanced glycation end-product N epsilon-(carboxymethyl)lysine is increased in uremia.

Degenhardt TP, Grass L, Reddy S, Thorpe SR, Diamandis EP, Baynes JW. Degenhardt TP, et al. Among authors: baynes jw. Kidney Int. 1997 Oct;52(4):1064-7. doi: 10.1038/ki.1997.429. Kidney Int. 1997. PMID: 9328946 Free article.

9

Chemical modification of proteins by methylglyoxal.

Degenhardt TP, Thorpe SR, Baynes JW. Degenhardt TP, et al. Among authors: baynes jw. Cell Mol Biol (Noisy-le-grand). 1998 Nov;44(7):1139-45. Cell Mol Biol (Noisy-le-grand). 1998. PMID: 9846896

10

Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats.

Degenhardt TP, Fu MX, Voss E, Reiff K, Neidlein R, Strein K, Thorpe SR, Baynes JW, Reiter R. Degenhardt TP, et al. Among authors: baynes jw. Diabetes Res Clin Pract. 1999 Feb;43(2):81-9. doi: 10.1016/s0168-8227(98)00121-1. Diabetes Res Clin Pract. 1999. PMID: 10221660

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

194 results

Search Page

Filters